TrialRMD open2026

Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial.

Teresa Holly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.